{"entity": "journal", "iuid": "f3d4445a73514362b3cdfd2ea65f4873", "timestamp": "2026-08-23T09:24:47.344Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/J%20Appl%20Lab%20Med.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/J%20Appl%20Lab%20Med"}}, "title": "J Appl Lab Med", "issn": "2576-9456", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "80fc82d4a197449ba117c3eb3d8d9c0f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/80fc82d4a197449ba117c3eb3d8d9c0f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/80fc82d4a197449ba117c3eb3d8d9c0f"}}, "title": "Patient-Centric Quantitative Microsampling for Accurate Determination of Urine Albumin to Creatinine Ratio (UACR) in a Clinical Setting.", "authors": [{"family": "L\u00f6fgren", "given": "Lars", "initials": "L"}, {"family": "von Euler Chelpin", "given": "Marianne", "initials": "M"}, {"family": "Bhat", "given": "Maria", "initials": "M"}, {"family": "Althage", "given": "Magnus", "initials": "M"}, {"family": "Hober", "given": "Andreas", "initials": "A", "orcid": "0000-0001-8947-2562", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/06cbc187628340278395a00ab9dd6c89.json"}}, {"family": "Edfors", "given": "Fredrik", "initials": "F"}, {"family": "Ruckh", "given": "Tim", "initials": "T"}, {"family": "Challis", "given": "Benjamin", "initials": "B"}, {"family": "Davidsson", "given": "Pia", "initials": "P", "orcid": "0000-0002-4775-5828", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a62589743acc4ae3967b343bf4bb3d33.json"}}, {"family": "Miliotis", "given": "Tasso", "initials": "T", "orcid": "0000-0003-4917-0724", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0d5ba9b546949db95c9b8597bd1fe7e.json"}}], "type": "journal article", "published": "2024-03-01", "journal": {"title": "J Appl Lab Med", "issn": "2576-9456", "volume": "9", "issue": "2", "pages": "329-341", "issn-l": null}, "abstract": "Developing and implementing new patient-centric strategies for drug trials lowers the barrier to participation for some patients by reducing the need to travel to research sites. In early chronic kidney disease (CKD) trials, albuminuria is the key measure for determining treatment effect prior to pivotal kidney outcome trials.\n\nTo facilitate albuminuria sample collection outside of a clinical research site, we developed 2 quantitative microsampling methods to determine the urinary albumin to creatinine ratio (UACR). Readout was performed by LC-MS/MS.\n\nFor the Mitra device the within-batch precision (CV%) was 2.8% to 4.6% and the between-batch precision was 5.3% to 6.1%. Corresponding data for the Capitainer device were 4.0% to 8.6% and 6.7% to 9.0%, respectively. The storage stability at room temperature for 3 weeks was 98% to 103% for both devices. The recovery for the Mitra and Capitainer devices was 104% (SD 7.0%) and 95 (SD 7.4%), respectively. The inter-assay comparison of UACR assessment generated results that were indistinguishable regardless of microsampling technique. The accuracy based on LC-MS/MS vs analysis of neat urine using a clinical chemistry analyzer was assessed in a clinical setting, resulting in 102 \u00b1 8.0% for the Mitra device and 95 \u00b1 10.0% for the Capitainer device.\n\nBoth UACR microsampling measurements exhibit excellent accuracy and precision compared to a clinical chemistry analyzer using neat urine. We applied our patient-centric sampling strategy to subjects with heart failure in a clinical setting. Precise UACR measurements using quantitative microsampling at home would be beneficial in clinical drug development for kidney therapies.", "doi": "10.1093/jalm/jfad111", "pmid": "38113397", "labels": [], "xrefs": [{"db": "pii", "key": "7479657"}], "notes": [], "created": "2026-08-20T09:42:02.090Z", "modified": "2026-08-20T09:42:02.234Z"}, {"entity": "publication", "iuid": "1f41dba60d564a4a9762fe746b8742fd", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/1f41dba60d564a4a9762fe746b8742fd.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/1f41dba60d564a4a9762fe746b8742fd"}}, "title": "Microfluidic Immunoaffinity Basophil Activation Test for Point-of-Care Allergy Diagnosis.", "authors": [{"family": "Aljadi", "given": "Zenib", "initials": "Z"}, {"family": "Kalm", "given": "Frida", "initials": "F"}, {"family": "Ramachandraiah", "given": "Harisha", "initials": "H"}, {"family": "Nopp", "given": "Anna", "initials": "A"}, {"family": "Lundahl", "given": "Joachim", "initials": "J"}, {"family": "Russom", "given": "Aman", "initials": "A"}], "type": "evaluation study", "published": "2019-09-00", "journal": {"title": "J Appl Lab Med", "issn": "2576-9456", "volume": "4", "issue": "2", "pages": "152-163", "issn-l": null}, "abstract": "The flow cytometry-based basophil activation test (BAT) is used for the diagnosis of allergic response. However, flow cytometry is time-consuming, requiring skilled personnel and cumbersome processing, which has limited its use in the clinic. Here, we introduce a novel microfluidic-based immunoaffinity BAT (miBAT) method.\n\nThe microfluidic device, coated with anti-CD203c, was designed to capture basophils directly from whole blood. The captured basophils are activated by anti-Fc\u03b5RI antibody followed by optical detection of CD63 expression (degranulation marker). The device was first characterized using a basophil cell line followed by whole blood experiments. We evaluated the device with ex vivo stimulation of basophils in whole blood from healthy controls and patients with allergies and compared it with flow cytometry.\n\nThe microfluidic device was capable of capturing basophils directly from whole blood followed by in vitro activation and quantification of CD63 expression. CD63 expression was significantly higher (P = 0.0002) in on-chip activated basophils compared with nonactivated cells. The difference in CD63 expression on anti-Fc\u03b5RI-activated captured basophils in microfluidic chip was significantly higher (P = 0.03) in patients with allergies compared with healthy controls, and the results were comparable with flow cytometry analysis (P = 0.04). Furthermore, there was no significant difference of CD63% expression in anti-Fc\u03b5RI-activated captured basophils in microfluidic chip compared with flow cytometry.\n\nWe report on the miBAT. This device is capable of isolating basophils directly from whole blood for on-chip activation and detection. The new miBAT method awaits validation in larger patient populations to assess performance in diagnosis and monitoring of patients with allergies at the point of care.", "doi": "10.1373/jalm.2018.026641", "pmid": "31639660", "labels": [], "xrefs": [{"db": "pii", "key": "jalm.2018.026641"}], "notes": [], "created": "2026-08-20T12:45:04.906Z", "modified": "2026-08-20T12:45:04.952Z"}], "created": "2026-08-20T09:42:02.197Z", "modified": "2026-08-20T09:42:02.197Z"}